ESLAW
Estrella Immunopharma, Inc.
Set alert
0.07 USD 0.00 0.00%
0.0701 Day range 0.0701
0.0701 52-week range 0.0701
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.11
- Prev close
- 0.0701
- Mkt cap
- 22.23M
- Vol
- 4.30K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0701
- High
- 0.0701
- Forward P/E
- 0.00
- Beta
- -0.09
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Financial health
Altman Z-Score
-53.07 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -4.5×
FY 2020 5y median -5.2× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B -5.5×
FY 2020 5y median 9.1× FY 2025
P/FCF -32.2×
FY 2020 5y median -32.2× FY 2025
EV/EBITDA -4.3×
FY 2020 5y median -4.9× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -3.1%
FY 2020 5y median -3.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE 126.0%
FY 2020 5y median -157.2% FY 2025
ROIC 126.0%
FY 2020 5y median -51.5% FY 2025
ROA -411.2%
FY 2020 5y median -164.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -47.7%
FY 2020 FY 2025
EPS (diluted) -45.8%
FY 2020 FY 2025
Free Cash Flow 42.6%
FY 2020 FY 2025
Financial Health
Current Ratio 0.1×
FY 2020 5y median 0.5× FY 2025
Quick Ratio 0.1×
FY 2020 5y median 0.5× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 0.1×
FY 2020 5y median 0.1× FY 2025
Interest Coverage 0.0×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31